KR20020011856A - Cyclooxygenase Inhibitor, and Food and Beverage containg the Same - Google Patents

Abstract

PURPOSE: To provide a cyclooxygenase inhibitor free from side action and having excellent taste and provide food and drink containing the inhibitor. CONSTITUTION: The active component of the inhibitor is α-mangostin and γ- mangostin extracted from the skin of mangosteen fruit with a water-containing organic solvent or an organic solvent.

Description

Cyclooxygenase Inhibitor, and Food and Beverage containg the Same}

The present invention relates to a cyclooxygenase inhibitor derived from mangosteen and a food and drink having a cyclooxygenase inhibitor containing the same.

Most of the cyclooxygenase inhibitors represented by aspirin and indomethacin have an effect of inhibiting prostaglandin biosynthesis, so most of the cyclooxygenase inhibitors currently used are digestible. Since there are side effects such as ulcers and dizziness, and there is no significant difference between the amount used for treatment and the amount of side effects expressed, there is a demand for the development of a higher safety cyclooxygenase inhibitor.

Moreover, when the cyclooxygenase inhibitor of the related art is added to food and drink, there is a fear that the value of the commodity may be remarkably reduced by affecting taste and flavor.

On the other hand, the fruit of mangosteen (Garcinia mangostana L) is used as a general method of edible flesh, and the skin is used as a folk medicine in Thailand of origin, to stop diarrhea or to treat wounds.

As another method of using the skin of mangosteen (Garcinia mangostana L.), a preservative for food in Japanese Patent Application Laid-Open Nos. 6-98738 and 7-147951, and 5α-reducta in Publication No. 5-17365 An agonist inhibitor, an antimicrobial agent in Japanese Patent Laid-Open No. 7-250658, an anti-helicobacter pylori drug in Japanese Patent Laid-Open No. 8-208501, an ultraviolet absorber in Japanese Patent Laid-Open No. 9-87155, and a serine protease inhibitor in Japanese Patent Laid-Open No. 10-120586 It is.

Moreover, about the water-soluble extract of the mangosteen (Garcinia mangostana L.) rind, Japanese Patent Application Laid-Open No. 4-244004 discloses a whitening, anti-inflammatory action, and mangosteen (Garcinia mangostana L.) according to histamine release from mast cells. For the polar solvent extract of the skin, α-mangosteen and γ-mangosteen, Japanese Patent Application Laid-Open No. 10-72357 discloses antiallergic action according to antagonism of histamine and serotonin.

However, in the prior art, there is nothing related to the cyclooxygenase inhibitory effect of the mangosteen (Garcinia mangostana L.).

SUMMARY OF THE INVENTION An object of the present invention is to provide a cyclooxygenase inhibitor which is safe without side effects, has excellent taste and stability, and has a strong cyclooxygenase inhibitory action, and a net rice containing the same as an active ingredient. It is to provide the food-drinks for cyclooxygenase inhibition excellent in (iii).

MEANS TO SOLVE THE PROBLEM This inventor performed earnest research in order to solve the said subject, extracts it with the various solvents from the peel of mangosteen (Garcinia mangostana L.), and isolates the several components contained in the extract. , As a result of confirming the effect as a cyclooxygenase inhibitor on its extracts and components, the extract obtained by extracting with a water-containing organic or organic solvent from the skin of mangosteen and α- mangosteen represented by the formula It was found that γ-mangosteen represented by 2 had excellent cyclooxygenase inhibitory activity, and completed the present invention.

That is, this invention is the extract obtained by extracting with the organic organic solvent or the organic solvent from the skin of mangosteen, and the cyclooxygenase inhibitor which uses alpha-mangosteen and gamma-mangosteen as an active ingredient.

Moreover, this invention is the food-drinks for cyclooxygenase inhibition excellent in the taste and flavor containing the said cyclooxygenase inhibitor.

The extract obtained by extracting the organic or organic solvent from the skin of mangosteen, the active ingredient of the present invention, is obtained from the fruits (raw or dried) of mangosteen (Garcinia mangostana L.) of the Asteraceae. use. The skin of mangosteen may be used as it is, but it is preferable to dry, pulverize and use it as a powder, since extraction efficiency improves. The skin of mangosteen may be degreased with a nonpolar solvent such as n-hexane or petroleum ether before extracting the peel of mangosteen with a water-containing organic solvent or an organic solvent.

As the extraction solvent, organic solvents such as methanol, ethanol, n-propanol, isopropanol, n-butanol, acetone, ethyl acetate, diethyl ether, chloroform, glycerin, ethyl glycol and propyl glycol, preferably polar solvents, in particular ethanol Alcohol or an organic solvent mixed with water is used. The mixing ratio with water is not particularly limited, but the ratio of water is preferably 70% v / v or less, more preferably 60% v / v or less. Regarding the extraction temperature, considering the extraction efficiency, the reflux temperature of the solvent from room temperature is preferable. The extraction time varies depending on the type of extraction solvent, the pulverized state of the skin and the extraction temperature, but 0.5 hours to 24 hours are preferable.

The extract obtained by extraction from the extraction solvent may be concentrated or removed by using an evaporator or the like as necessary.

Although α-mangosteen and γ-mangosteen, which are the active ingredients of the present invention, can be extracted and purified from a fruit of mangosteen (Garcinia mangostana L.) by a known method, a synthesized one can also be used. Do.

The cyclooxygenase inhibitor of the present invention thus obtained is effective for the treatment and prevention of diseases in which prostaglandins are involved as pathogenic agents, for example, symptoms related to pain, fever, inflammation, influenza or other viral infections, Cold, pharyngitis, pharyngeal pain, bronchitis, tonsillitis, periodontitis, alveolaritis, toothache, gingivitis, gout, arthritis, nephritis, hepatitis, bronchitis, dysmenorrhea, headache, ulcerative colitis, sprain and sprain due to bacterial infection It can be used for the treatment, prevention of myalgia, neuralgia, periostitis, burns, and inflammation after surgical and dental treatment.

Moreover, the cyclooxygenase inhibitor of this invention can inhibit the proliferation and metastasis of the tumor cell which cyclooxygenase participates, and can also be used for cancer treatment and cancer prevention, such as colorectal cancer.

In addition, the cyclooxygenase inhibitor of the present invention, by the ability to inhibit prostaglandin-induced smooth muscle contraction by interfering with the synthesis of contractile prostaglandins, treatment of dysmenorrhea, premature delivery, bone defects (treatment of deformed arthrosis), frequent urination, It can be used for urinary incontinence therapy, myocardial infarction and prevention and treatment of cerebral hemorrhage.

Moreover, the cyclooxygenase inhibitor of this invention is effective also in sleep prevention by the effect which inhibits sleep by prostaglandin by interfering with the synthesis | combination of a sleep-induced prostaglandin.

Cyclooxygenase inhibitors of the present invention, the aqueous organic solvent or organic solvent extract of the skin of the mangosteen (Garcinia mangostana L.) and α- mangosteen and γ- mangosteen, alone or in the form of other pharmaceutical or carrier It can be mixed with a diluent, etc., or can be used as a medicine in arbitrary formulations. For example, it is possible to exemplify tablets, granules, fine granules, hard capsules, soft capsules, oral solution preparations, injections and the like as the formulation.

Moreover, the food-drinks for cyclooxygenase inhibition of this invention mix and manufacture the mangosteen extract which is a cyclooxygenase inhibitor of this invention, and at least 1 sort (s) of (alpha) -mangosteen and (gamma) -mangosteen to various foods, and to manufacture. It is possible. For example, as a food and drink for cyclooxygenase inhibition, a soft drink, a confectionery, a frozen dessert, dairy products, alcoholic beverages, meat, etc. are mentioned.

The effective amount of mangosteen extract and α-mangosteen and γ-mangosteen, which are the active ingredients of the cyclooxygenase inhibitor of the present invention, vary depending on the administration method and the necessary treatment, and it is difficult to define one mangosteen. The extract has a dry weight of 0.5 mg to 500 mg per kilogram of animal body weight, and the preferred fighting amount per day for adults (70 kg) is 5 mg to 5 g, more preferably 5 mg to 1 g, α-mangosteen and For gamma-mangosteen, the preferred combat amount per day is 0.1 mg to 100 mg per adult body weight, and for adults (70 kg), 1 mg to 1000 mg, more preferably 5 mg to 500 mg.

The content of mangosteen extract as an active ingredient and α-mangosteen and γ-mangosteen as an active ingredient in the cyclooxygenase inhibitory food or drink of the present invention satisfies the above-mentioned effective amount in a daily intake as a food or drink. It is possible to define content so that it may be made.

Hereinafter, the present invention will be described in more detail with reference to Examples, but the scope of the present invention is not limited to the following Examples.

Example

First, an example of preparing an extract having a cyclooxygenase inhibitory activity and α-mangosteen and γ-mangosteen from the skin of mangosteen (Garcinia mangostana L.), and then inhibiting its prostaglandin biosynthesis, cycloox The test method and results confirming the inhibitory action of the cagenase are shown, and examples of the cyclooxygenase inhibitor and the cyclooxygenase inhibitory food and drink for the present invention are shown.

Example 1 Mangosteen Methanol Extract

1 kg of undried peel of mangosteen (Garcinia mangostana L.) was immersed in 10 L of methanol, and extracted at room temperature for 24 hours. After filtration, the filtrate was dried under reduced pressure in an evaporator to obtain 80 g of the cyclooxygenase inhibitor of the present invention.

Example 2 Mangosteen 40% Ethanol Extract

500 g of dried and peeled powder of mangosteen (Garcinia mangostana L.) was immersed in 5 L of 40% ethanol and extracted at room temperature for 24 hours. After filtration, the filtrate was dried under reduced pressure with an evaporator to obtain 104 g of a cyclooxygenase inhibitor of the present invention.

Example 3 Mangosteen 70% Ethanol Aqueous Extract

480 g of dried and skin powder of Mangosteen (Garcinia mangostana L.) were extracted with 5 L of 70% ethanol for 4 hours (60 ° C). After filtration, the filtrate was dried under reduced pressure with an evaporator to yield 128 g of the cyclooxygenase inhibitor of the present invention.

Example 4 Mangosteen Ethanol Extract

1.1 kg of dried and peeled powder of mangosteen (Garcinia mangostana L.) were extracted with 11 L of ethanol for 4 hours (60 ° C). After filtration, the filtrate was dried under reduced pressure with an evaporator to obtain 128 g of the cyclooxygenase inhibitor of the present invention.

Example 5 Preparation of α-mangosteen and γ-mangosteen

80 g of the extract of Example 1 was dissolved in 350 ml of ethyl acetate, and then washed twice with 200 ml of water. The remaining amount of ethyl acetate was distilled off the solvent by an evaporator to obtain 20 g of dried product. This dried product was purified by silica gel column chromatography. The elution was gradually eluted with a hexane-ethyl acetate system to give three fractions. The first obtained fraction (5 g) was once again purified by silica gel column chromatography (hexane-ethyl acetate, 10:90-> 30: 70-> 50: 50) to give 2 g of? -Mangosteen as yellow crystals. The second fraction (2 g) was once again purified by silica gel column chromatography (hexane-ethyl acetate 30:70 to 50:50, ethyl acetate only, finally ethyl acetate, 50:50) to give a yellow amorphous γ. -500 mg of mangosteen was obtained.

Test Example 1 Prostaglandin Biosynthesis Inhibition Test

To a 6-hole plate was added F-10 Nutrient Mixure (Ham) medium containing 15% horse serum and 2.5% fetal bovine serum and C 6 rat glycoma cells to 1.0 x 10 ⁵ cells / ml. The cells were incubated for 3 days at 37 ° C. in a 5% CO ₂ incubator. Then, the test substance was added and incubated for 10 minutes at 37 degreeC, and 100 micrometers of 100 micrometers Ca ionization A 23187 was added, and it cultured for 10 minutes. The reaction stop solution (100 micrometers indomethacin 50mM EDTA) previously cooled with ice was added, and the culture supernatant was collect | recovered. 1N hydrochloric acid was added to the culture supernatant to pH 4, ethyl acetate was added thereto, and the resulting prostaglandin E ₂ was transferred to the ethyl acetate layer. The ethyl acetate layer was recovered, dried under reduced pressure, and dissolved in 0.5 ml of 10 mM Tris-HCl buffer (pH 7.6). [3H] prostaglandin E ₂ solution and prostaglandin E ₂ antibody were added to this solution, and the mixture was reacted at 4 ° C for 24 hours. Then, charcoal liquid was added and centrifuged, the supernatant radioactivity was measured by the liquid scintillation counter, and the amount of free prostaglandin E ₂ in the medium was quantified. The decrease in prostaglandin E ₂ production according to the test substance to the prostaglandin E ₂ production of the control containing no test substance was expressed as the prostaglandin E ₂ production inhibition rate. The results are shown in Table 1.

sample Sample concentration Prostaglandin E ₂ production inhibition rate (%) Control 30 μM 0.0 α-mangosteen 30 μM 97.2 γ-mangosteen 100 μg / ml 90.2 Mangosteen Water Extract 100 μg / ml -32.7 Extract of Example 2 100 μg / ml 87.1 Extract of Example 3 100 μg / ml 100.0 Extract of Example 4 100 μg / ml 84.9

Test Example 2 Cyclooxygenase Inhibition Test

Both seminal vesicle microsomes are used as cyclooxygenase. The cyclooxygenase reaction was carried out at 0.1 M phosphate buffer (pH 7.5) containing both seminal vesicle microsomal at a final concentration of 270 μg / ml, 5 mM tripptophan, 1 mM phenol, 0.23 mM hydrokinone, 1 μM hexane, 20 μM arachidonic acid. The test substance dissolved in methanol was added to the mixture, and reacted at 37 ° C for 10 minutes. The reaction solution was boiled to stop the reaction, and the amount of prostaglandin E _{2 in the} supernatant was quantified by EIA. The decrease in the amount of prostaglandin E 2 produced by the test subject to the amount of prostaglandin E 2 produced by the control which did not contain the test substance was expressed by the ratio of cyclokisagease. The results are shown in Table 2.

sample Sample concentration Prostaglandin E ₂ production inhibition rate (%) Extract of Example 2 100 μg / ml 93.1 Extract of Example 3 10 μg / ml 40.9 Extract of Example 3 100 μg / ml 90.4 Extract of Example 4 10 μg / ml 59.8 Extract of Example 4 100 μg / ml 97.5 α-mangosteen 10 μg / ml 70.2 α-mangosteen 100 μg / ml 93.3 γ-mangosteen 10 μg / ml 83.8 γ-mangosteen 100 μg / ml 97.7

In the results of these test examples 1 and 2, the mangosteen extract, α-mangosteen and γ-mangosteen of the present invention have prostaglandin biosynthesis inhibitory activity, and also the mangosteen extract, α-mangosteen and γ- of the present invention. Because mangosteen has a cyclooxygenase inhibitory effect, the present invention is useful for the treatment and prevention of diseases in which prostaglandins of mammals are involved as pathogenic agents.

Example 6 Powder

Lactose 25

10 parts potato starch

5 parts extract of Example 1

Example 7 Tablets

D-mannitol part 10

Lactose, Part 10

Crystalline Cells Part 2

Hydroxypropyl Cellulose Part 1

α-mangosteen 0.5part

Example 8 Syrups

Sweet syrup part 10

Carboxymethylcellulose, part 1

γ-mangosteen 0.3 part

Example 9 Injection

0.5 part chlorobutanol

Sodium chloride0.9part

100 parts of water for injection

1 part extract of Example 2

Example 10 Candy

45 parts per granule

Starch syrup (D.E. 42) 50

20 parts water

γ-mangosteen 0.5part

Lemon Flavors, Part 1

Example 11 Chocolate

Kakaobiter, part 20

Kakaover Part 17

43 parts of sugar

20 parts powder

1 part extract of Example 2

0.5 Vanilla Flavors

Example 12 Chewing Gum

20 gum bases

56 parts sugar

Starch syrup part 13

10 parts glucose

Softener Part 1

0.5 part extract of Example 3

Mint Flavor 0.5

Example 13

75 parts sugar

Glucose Part 19

0.2 part sucrose fatty acid ester

0.5 part extract of Example 4

4 parts water

The extract obtained by extracting a water-containing organic or organic solvent from the skin of the mangosteen of the present invention, the cyclooxygenase inhibitor containing α-mangosteen and γ-mangosteen as an active ingredient, can be prepared from natural products and has no side effects. Since it is safe and has excellent cyclooxygenase inhibitory effect and prostaglandin biosynthesis inhibitory effect, it is effective for the prevention and treatment of the disease resulting from this.

Moreover, the cyclooxygenase inhibitor of this invention can provide the food-drinks for cyclooxygenase inhibition which are excellent in taste and excellent in taste by including this in food-drinks.

Claims (4)

A cyclooxygenase inhibitor, characterized in that the extract obtained from the extract of mangosteen (Garcinia mangostana L.) with a hydrous organic solvent or an organic solvent as an active ingredient. The chemical formula below Cyclooxygenase inhibitor, characterized in that the α- mangosteen represented by the active ingredient. The chemical formula below Cyclooxygenase inhibitor, characterized in that γ-mangosteen represented by the active ingredient. A food and beverage for cyclooxygenase inhibition, comprising the cyclooxygenase inhibitor according to any one of claims 1 to 3.